Innocan Pharma

Innocan Pharma FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Innocan Pharma (INNO.CN) as of Oct 17, 2026 is 86.91 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 84.04 % — a change of 3.42% (higher).

FCF Conversion

86.91 %

YoY

3.42%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Innocan Pharma is 2024 86.91 % . FCF Conversion Rate (FCF/EBITDA) of Innocan Pharma was 2023 84.04 % . It decreases by 3.42% higher compared to the previous year.

The Innocan Pharma FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2017
0.00 USD
Jan 1, 2018
76.51 USD
Jan 1, 2019
81.68 USD
Jan 1, 2020
37.04 USD
Jan 1, 2021
66.39 USD
Jan 1, 2022
161.88 USD
Jan 1, 2023
84.04 USD
Jan 1, 2024
86.91 USD
The Innocan Pharma FCF Conversion history
YEARFCF ConversionYoY
86.91 %+3.42%
84.04 %-48.08%
161.88 %+143.83%
66.39 %+79.21%
37.04 %-54.65%
81.68 %+6.76%
76.51 %—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Innocan Pharma Stock analysis

What does Innocan Pharma do? InnoCan Pharma Corp, based in Herzliya, Israel, operates in the Health Care sector as a pharmaceutical technology company. The company focuses on three segments: developing and distributing its own OTC pharmaceutical products, conducting R&D for non-pharmaceutical products for third parties, and creating hydrogels with liposomes for licensing to pharmaceutical corporations. It is also advancing a new OTC topical treatment line and a platform for targeted cannabinoid delivery via injection. Innocan Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Innocan Pharma stock

FCF Conversion Rate (FCF/EBITDA) of Innocan Pharma is 86.91 % in 2024.

FCF Conversion Rate (FCF/EBITDA) of Innocan Pharma changed from 84.04 % to 86.91 %, representing a 3.42% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Innocan Pharma since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Innocan Pharma with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Innocan Pharma

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Innocan Pharma